“Both Jim Reich and Ray Farnham will be able to advance the sensor technology of our minimally invasive, cardiovascular implants and continue to develop our remote patient monitoring system.”
MENLO PARK, CA (PRWEB) April 14, 2016
GraftWorx, LLC, a new biotech company developing implantable technology for integrated remote patient monitoring, today announced two new members, Jim Reich, a pioneer of sensor technology, and Ray Farnham, former President of mCube, the provider of the world's smallest MEMS motion sensors.
“We are pleased to welcome the great talent and extensive expertise of Jim and Ray,” stated GraftWorx Co-Founder and CEO, David Kuraguntla. “Both Jim Reich and Ray Farnham will be able to advance the sensor technology of our minimally invasive, cardiovascular implants and continue to develop our remote patient monitoring system.”
Jim Reich joins the GraftWorx team as Director of Embedded Systems. He has built sensing and control systems for areas as diverse as spacecraft, cooking devices and parking sensor networks. He’s been an early employee or co-founder at several startups, including Streetline, the leading company in smart parking, where he built and operated one of the world’s largest sensor networks. Mr. Reich also led the pioneering sensor network group at Xerox PARC.
“I’ve been building and operating ultra-low-power wireless sensors for decades. But what I'm most excited about here at GraftWorx is giving doctors a new picture of what's going on in their patients’ bodies through a whole new class of lifesaving implantable sensors,” Mr. Reich commented.
Ray Farnham joins as COO. Previously, Farnham was President and CEO of mCube Inc., a MEMS technology company focusing on inertial sensors for the mobile market. Mr. Farnham was also the Chairman of NetEffect Semiconductor when it was sold to Intel in 2008. His extensive experience includes leadership roles in numerous technology companies, including IDS Software, Hifn, Integrated Device Technology and National Semiconductor.
When asked why he chose to work with GraftWorx, Mr. Farnham responded, “I’m excited to be a part of developing revolutionary, implantable technology that will offer integrated practice monitoring for patients, physicians and hospitals. This is a critical frontier for MEMS technology and patient-centered health care.”
In August of 2015, GraftWorx raised $1.9 million to support preclinical trials of its smart grafts that can actively detect and avoid impending artery blockages, thus preventing costly complications. Its next round of financing is underway.
About GraftWorx, LLC:
GraftWorx is turning the Internet of Things into the Internet of the Body. It is currently building cardiovascular stents and grafts with a seamlessly integrated sensor package that leverages its proprietary cloud software to change patient lives. The sensor package interrogates the device daily via a smartphone app. Their HIPAA-compliant cloud software is able to communicate, securely store and analyze data generated from the sensors. For more information, visit http://www.graftworx.com.
# # #